Patents by Inventor Luigi Warren

Luigi Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220008482
    Abstract: Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras.
    Type: Application
    Filed: June 13, 2019
    Publication date: January 13, 2022
    Inventor: Luigi WARREN
  • Patent number: 11186829
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 30, 2021
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20210196763
    Abstract: Methods for accelerated cell lineage conversion and the treatment of patients with the lineage converted cells are provided. The methods include the steps of transfecting a cell with a composition that includes at least one synthetic mRNA encoding a chimeric protein that corresponds to an engineered fusion of a transcription factor and an heterologous peptide sequence derived from the C-terminal TAD of Gal4. The TAD domain enhances the epigenetic remodeling activity of the chimeric protein increasing the speed of lineage conversion. The converted cells may be used for research or administered to a human or animal patient as a therapy. In one preferred embodiment, the reprogramming of a somatic cell to pluripotency is accelerated by using a cocktail of mRNAs expressing a combination of wild-type or engineered reprogramming factors where Oct4 and/or Sox2 and/or Nanog are expressed as Gal4 TAD chimeras.
    Type: Application
    Filed: June 13, 2019
    Publication date: July 1, 2021
    Inventor: Luigi WARREN
  • Patent number: 10815463
    Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 27, 2020
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Padmanabh Chivukula, Luigi Warren, Kiyoshi Tachikawa, Joseph E. Payne
  • Publication number: 20190382729
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Application
    Filed: May 28, 2019
    Publication date: December 19, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Patent number: 10344265
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: July 9, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Derrick Rossi, Luigi Warren
  • Patent number: 10155929
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: December 18, 2018
    Assignee: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.
    Inventors: Jiwu Wang, Luigi Warren, Yuhui Ni
  • Publication number: 20180216078
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Application
    Filed: August 31, 2017
    Publication date: August 2, 2018
    Applicant: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20180051262
    Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.
    Type: Application
    Filed: November 7, 2017
    Publication date: February 22, 2018
    Inventors: Padmanabh Chivukula, Luigi Warren, Kiyoshi Tachikawa, Joseph E. Payne
  • Patent number: 9803177
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: October 31, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20160130567
    Abstract: This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.
    Type: Application
    Filed: November 1, 2015
    Publication date: May 12, 2016
    Inventors: Padmanabh Chivukula, Luigi Warren, Kiyoshi Tachikawa, Joseph E. Payne
  • Patent number: 8883506
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: November 11, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20140308746
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 16, 2014
    Inventors: Derrick Rossi, Luigi Warren
  • Patent number: 8802438
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: August 12, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Patent number: 8716465
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: May 6, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20130302295
    Abstract: The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 14, 2013
    Inventors: Jiwu WANG, Luigi WARREN, Yuhui NI
  • Publication number: 20120322864
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Application
    Filed: August 21, 2012
    Publication date: December 20, 2012
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20120322865
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Application
    Filed: August 21, 2012
    Publication date: December 20, 2012
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Derrick Rossi, Luigi Warren
  • Publication number: 20120046346
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Application
    Filed: April 15, 2011
    Publication date: February 23, 2012
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Derrick Rossi, Luigi Warren